GlassScriptPhysician profile
Jose R Foradada
NPI 1841308475
$13,403.81
in general payments reported to CMS, 2019-2025
43 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 76% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $1,714 · 2021: $2,526 · 2022: $2,284 · 2023: $1,754 · 2024: $2,180 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,601.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $2,791.58 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Ucb, INC. | $2,177.08 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,087.43 | 2021-2025 | Epidiolex |
| Supernus Pharmaceuticals, INC. | $910.14 | 2019-2025 | Qelbree, Qelbree |
| Eisai INC. | $734.00 | 2019-2023 | |
| Corium, LLC | $693.72 | 2021-2025 | Azstarys |
| Noven Therapeutics, LLC | $473.62 | 2023-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $446.23 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $438.10 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $352.92 | 2019-2023 | Adzenys Xr-Odt |
| Neurelis, INC. | $304.64 | 2020-2025 | Valtoco |
| Aquestive Therapeutics, INC. | $300.10 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $289.33 | 2023-2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $211.00 | 2023-2025 | Fycompa |
| Greenwich Biosciences, INC. | $205.18 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Foradada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.